Drug Trial News

RSS

Study Confirms Comparable Efficacy of Lamotrigine and Mexiletine in Muscle Channelopathy

The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition.

30 Sep 2024

Surface Plasmon Resonance Sensors: Transforming Drug Development and Clinical Diagnostics

The latest developments in SPR-based biosensors and their applications in drug discovery.

15 Jul 2024

Arrowhead's Plozasiran Reduces Triglyceride Rich Lipoproteins in Patients with Mixed Hyperlipidemia

Arrowhead Pharmaceuticals, Inc. today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ARO-APOC3) in patients with mixed hyperlipidemia.

3 Jun 2024

Study Provides More Treatment Options for Severe COVID-19

Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis.

11 Jul 2023

New combination therapy regimen may reduce prostate cancer progression or death by 37%

TALAPRO-2, a study led by Neeraj Agarwal, MD, FASCO, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progression or death by 37%.

20 Mar 2023

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

20 Mar 2023

Cell therapy trial promises long-term improvement for patients with chronic heart failure

Physician-scientists at The Texas Heart Institute announced today the results of the largest cell therapy trial to date in patients with chronic heart failure due to low ejection fraction.

28 Feb 2023

Study: Oral verapamil improves the pancreas' insulin secretion in children with newly-diagnosed TID

Published in JAMA, a University of Minnesota led study shows that verapamil, a drug commonly used to treat high blood pressure and heart conditions, can have a beneficial effect on the pancreas in children with newly-diagnosed type 1 diabetes (T1D).

27 Feb 2023

Adults struggling with chronic constipation benefit from a vibrating capsule

A vibrating capsule designed to stir the colon to action appears to double the ability for adults struggling with debilitating chronic constipation to defecate more normally and without drugs, researchers report.

22 Feb 2023

Oral difelikefalin could reduce the intensity of itch in patients with notalgia paresthetica

Notalgia paresthetica-;a nerve disorder characterized by a persistent itch in the upper back-;is a common and underdiagnosed condition worldwide.

9 Feb 2023

Microbiome therapeutic linked to quality of life improvement in patients with recurrent C. diff infection

Kevin Garey, professor of pharmacy practice and translational research at the University of Houston College of Pharmacy is reporting the first well-controlled study to demonstrate that a microbiome therapeutic, SER-109, is associated with significant quality of life improvement in patients with the debilitating recurrent infection and disease caused by Clostridium difficile (or C. diff).

1 Feb 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Triple drug combination keeps people with metastatic colon cancer disease free for longer time

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.

24 Dec 2020

Combination treatment improves outcomes in advanced kidney cancer patients

An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.

24 Sep 2020

Combination regimen improves overall survival in acute myeloid leukemia patients

A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

13 Aug 2020

Aspirin may increase risk of disease progression in older adults with advanced cancer

Results from a recent clinical trial indicate that for older adults with advanced cancer, initiating aspirin may increase their risk of disease progression and early death.

11 Aug 2020

COVID-19 Prevention Network announces two trials to evaluate monoclonal antibodies

The COVID-19 Prevention Network (CoVPN) today announced two Phase 3 trials to determine whether monoclonal antibodies (mAbs) can prevent SARS-CoV-2, the virus that causes COVID-19.

11 Aug 2020

NIH clinical study to evaluate potential new therapeutics for mild, moderate COVID-19

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

5 Aug 2020

Cholesterol-lowering medication improves function of the coronary arteries

In a pilot study of people living with HIV or high levels of cholesterol, Johns Hopkins Medicine researchers found that a six-week course of a cholesterol-lowering medication improved the function of the coronary arteries that provide oxygen to the heart.

30 Jul 2020

UC Davis Health tests new antibody combination as potential treatment for COVID-19

Timothy Albertson, chair of internal medicine and specialist in pulmonary and critical care, is leading efforts at UC Davis Health to test a new antibody cocktail (REGN-COV2) as a prevention and treatment for COVID-19.

From The University of California, Davis 21 Jul 2020